NCT00796835View on ClinicalTrials.gov

A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

October 31, 2004

Conditions
Schizophrenia
Interventions
DRUG

ER OROS Paliperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00796835 - A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone | Biotech Hunter | Biotech Hunter